Trial Profile
A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 in Adults With Refractory Aggressive Non-Hodgkin Lymphoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Jan 2024
Price :
$35
*
At a glance
- Drugs Axicabtagene ciloleucel (Primary) ; Cyclophosphamide; Dexamethasone; Fludarabine; Steroids; Tocilizumab; Vasopressors
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms ZUMA-1
- Sponsors Kite Pharma
- 04 Jan 2024 Results of long-term outcomes of cohort 6 (N = 40), published in the Bone Marrow Transplantation
- 12 Dec 2023 Results of a post-hoc long-term exploratory 5-year and 6-year analysis presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results of an expanded analysis using tumor biopsy samples assessing impact of axi-cel treatment on the TME immune contexture and examined associations between immune cell subsets and relapse presented at the 65th American Society of Hematology Annual Meeting and Exposition